Comparison of Outcomes among Chronic Kidney Disease V Patients with COVID-19 at the National Kidney and Transplant Institute: A Retrospective Cohort Study

Table 3

Treatment given to CKD V patients with COVID-19 (n = 436).

	All patients (n = 436); n(%)	HD (n = 298); n(%)	PD (n = 103); n(%)	Dialysis initiation (n = 35); n(%)	value
Hydroxychloroquine	27(6)	20(7)	5(5)	2(6)	0.791^a
Lopinavir/ritonavir	12(2)	11(4)	1(1)	0	0.203^a
Tocilizumab
1 dose	18(4)	15(5)	0	3(9)	0.033^a
2 doses	2(1)	1(1)	1(1)	0	0.533^b
Favipiravir	4(1)	2(1)	1(1)	1(3)	0.324^b
Hemoperfusion	43(10)	35(12)	5(5)	3(9)	0.125^a
Convalescent plasma	5(1)	4(1)	0	1(3)	0.292^b

^aChi-square test was used; ^bFisher’s exact test was used.